NASDAQ:BMRN

BioMarin Pharmaceutical Earning Date

USA |NASDAQ |USD

BMRN Earnings Date

|
Report Date Period Ending EPS Forecast Last Quarter's EPS Last Year's EPS
Oct 27, 2021 Sep 2021 $-0.24 $0.53 $0.50
Report Date Period Ending Revenue Forecast Last Quarter’s Revenue Last Year’s Revenue
Oct 27, 2021 Sep 2021 $435.89M $501.69M $476.78M

Biomarin Pharmaceutical's next earnings date is Wednesday, Oct 27, 2021 for the fiscal quarter ending Sep 2021.

BMRN Earnings Date & History Chart

BMRN Earnings & Revenue Forecast

BMRN Earnings Forecast

|
Period End # of Analysts EPS Forecast Low EPS Forecast High EPS Forecast
Dec 2021 15 $-0.35 $-0.57 $-0.03
Period End # of Analysts EPS Forecast Low EPS Forecast High EPS Forecast
Dec 2021 20 $-0.28 $-0.65 $1.28
Dec 2022 20 $0.92 $-0.44 $3.32

BMRN Earnings Revision Trend

|
Period End Up/Down 1M 1M Trend 2M Trend 3M Trend
Dec 2021 1 / 0 $-0.36 $-0.33 $-0.30
Period End Up/Down 1M 1M Trend 2M Trend 3M Trend
Dec 2021 1 / 0 $-0.36 $-0.35 $-0.52
Dec 2022 0 / 1 $0.92 $0.96 $0.90

BMRN Revenue Forecast

|
Period End # of Analysts Revenue Forecast Low Revenue Forecast High Revenue Forecast
Dec 2021 17 $430.90M $380.20M $476.00M
Period End # of Analysts EPS Forecast Low EPS Forecast High EPS Forecast
Dec 2021 21 $1.85B $1.80B $1.90B
Dec 2022 21 $2.18B $1.84B $2.54B

BMRN Earnings Date & Revenue History

BMRN Earnings History

|
Show More
Show More

BMRN Revenue History

|
Show More
Show More

Biomarin Pharmaceutical Next Earnings Date & Report

BMRN Next Earnings Date & Report Preview: Sep 2021 (FQ)

BMRN's next earnings date is Wednesday, Oct 27, 2021 for the fiscal quarter ending Sep 30, 2021.

According to 15 analysts, the average EPS estimation for Biomarin Pharmaceutical's next quarterly earnings is $-0.24, with a low EPS estimation of $-0.32, and a high estimation of $-0.08.

Over the last 1 month, EPS estimates have seen 1 upward revisions and 0 downward. The EPS 1 month trend is $-0.24, the last 2 month trend is $-0.23, and the 3 month trend is $-0.20.

Based on 17 analysts, the average revenue estimation is $435.89M, with a low revenue estimation of $405.33M, and a high estimation of $472.60M.

Biomarin Pharmaceutical Previous Earnings Dates & Reports

BMRN Previous Earnings Date & Report Recap: Jun 2021 (FQ)

Biomarin Pharmaceutical's previous earnings date was Jul 28, 2021 for its fiscal quarter ended Jun 30, 2021.

BMRN's earnings per share (EPS) was $0.53, beating the consensus analysts forecast of $0.25 by 107.64%.

The EPS was lower than the previous fiscal quarter (Mar 2021) by -6.87%, and higher than the same period a year before (Jun 2020) by 66.06%.

Revenues were $501.69M, better than the forecast of $448.79M by 11.79%, up by 3.21% from the previous quarter , and up by 16.81% from the same period last year.

The company reported a net income of $12.94M.

Free cash flow for the quarter was $56.53M , compared to $85.26M last quarter and $-5.75M a year before.

BMRN ended the quarter with $1.09B in total debt, an increase of 0.07% compared to the previous quarter, and a decrease of -24.61% compared to the same quarter a year before.

BMRN Previous Earnings Date & Report Recap: Dec 2020 (FY)

Biomarin Pharmaceutical's previous annual earnings date was Feb 25, 2021 for its fiscal year ended Dec 31, 2020.

BMRN's earnings per share (EPS) was $1.65, missing the consensus analysts forecast of $4.03 by -58.97% , and higher than the previous year's EPS (Dec 2019) by 81.88%.

Revenues were $1.86B, better than the forecast of $1.86B by 0.00%, and up by 9.18% from previous year's revenue.

The company reported a net income of $859.10M.

Biomarin Pharmaceutical reported a free cash flow of $-52.15M for its fiscal year, compared to $-115.14M a year ago.

The company ended the fiscal year with $1.09B in total debt, an increase of 26.56% compared to the previous year.